Abstract：
In Japan, cutaneous adverse events (AEs) following the coronavirus disease 2019 (COVID-19) vaccination have been frequently described; however, a larger case series and literature review are lacking. There is an urgent need for an extensive investigation of new cases and previous reports to provide a thorough body of information about post-COVID-19 immunization cutaneous AEs. We aimed to analyze patients with cutaneous AEs after COVID-19 vaccination in our hospital and review previous studies of cutaneous AEs. We analyzed post-COVID-19 vaccination cutaneous AEs in our department, the Japanese Registry, and previous literature. We enrolled 30 patients with cutaneous post-vaccination AEs in our department over 2 years (April 1, 2021, to March 31, 2023). We also confirmed cases registered in the Ministry of Health, Labor, and Welfare COVID-19 vaccine side effect reporting system (February 17, 2021-March 12, 2023). A total of 587 records were retrieved and 93 articles were included for data extraction. A total of 28 non-injection-site cutaneous AEs and two injection-site AEs were identified. Six (20.0%) patients developed new-onset erythematous eruptions, and five (16.7%) patients developed urticaria. Pruritic eruption, eczema, shingles, and sweating symptoms have also been reported. In previous studies on non-injection-site cutaneous AEs, individuals who received the BNT162b2 vaccine were older than those who received mRNA-1273 (P < 0.01). Cutaneous AEs were mostly nonsignificant and self-limiting reactions; however, rare, severe, or life-threatening AEs were also reported. Physicians should be aware of the various possible cutaneous AEs associated with the COVID-19 vaccination.
摘要：
在日本,2019年冠状病毒病(COVID-19)疫苗接种后的皮肤不良事件(AE)经常被描述；然而，缺乏更大的病例系列和文献综述。迫切需要对新病例和以前的报告进行广泛调查，以提供有关COVID-19免疫后皮肤AE的全面信息。我们旨在分析在我院接种COVID-19疫苗后出现皮肤AE的患者，并回顾以往皮肤AE的研究。我们分析了我们部门的COVID-19疫苗接种后的皮肤AE，日本登记处,和以前的文献。我们在我们部门招募了超过2年（2021年4月1日至2023年3月31日）的30例皮肤疫苗接种后AE患者。我们还确认了卫生部登记的病例，劳工,和福利COVID-19疫苗副作用报告系统（2021年2月17日-2023年3月12日）。共检索到587条记录，并包括93篇文章进行数据提取。总共鉴定了28种非注射部位皮肤AE和2种注射部位AE。六名(20.0%)患者出现新发红斑疹,5例(16.7%)患者出现荨麻疹。瘙痒性喷发,湿疹,带状疱疹,和出汗症状也有报道。在以前关于非注射部位皮肤AE的研究中，接受BNT162b2疫苗的个体比接受mRNA-1273的个体年龄大(P<0.01)。皮肤AE大多是无意义的自限性反应；然而，罕见,严重,也报告了危及生命的AE。医生应该意识到与COVID-19疫苗接种相关的各种可能的皮肤AE。
